Drug profile · INN
sulfamethoxazole
SULFAMETHOXAZOLE AND TRIMETHOPRIM
sulfamethoxazole (SULFAMETHOXAZOLE AND TRIMETHOPRIM) is a bacterial dihydropteroate synthase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — sulfamethoxazole
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 10
- Data quality
- 0.89
Quick answer
sulfamethoxazole (SULFAMETHOXAZOLE AND TRIMETHOPRIM) is a bacterial dihydropteroate synthase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial dihydropteroate synthase inhibitor
Primary target: Dihydropteroate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sulfamethoxazole?
sulfamethoxazole (SULFAMETHOXAZOLE AND TRIMETHOPRIM) is a bacterial dihydropteroate synthase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for sulfamethoxazole?
SULFAMETHOXAZOLE AND TRIMETHOPRIM is a marketed brand name for sulfamethoxazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sulfamethoxazole?
sulfamethoxazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.